Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 856

Similar articles for PubMed (Select 17382161)

1.

Intermediate-risk localized prostate cancer in the PSA era: radiotherapeutic alternatives.

Gondi V, Deutsch I, Mansukhani M, O'Toole KM, Shah JN, Schiff PB, Katz AE, Benson MC, Goluboff ET, Ennis RD.

Urology. 2007 Mar;69(3):541-6.

PMID:
17382161
2.

Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.

Fitch DL, McGrath S, Martinez AA, Vicini FA, Kestin LL.

Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1430-9. Epub 2006 Jun 12.

PMID:
16765527
3.
4.

Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.

Kupelian P, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A, Kuban D.

Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):795-9. Epub 2005 May 31.

PMID:
15925452
5.

Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.

Kollmeier MA, Stock RG, Stone N.

Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):645-53.

PMID:
14529768
6.

Biochemical relapse-free survival in 400 patients treated with I-125 prostate brachytherapy: the Guildford experience.

Nobes JP, Wells IG, Khaksar SJ, Money-Kyrle JF, Laing RW, Langley SE.

Prostate Cancer Prostatic Dis. 2009;12(1):61-6. doi: 10.1038/pcan.2008.17. Epub 2008 Apr 22.

PMID:
18427571
8.

Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer.

Kupelian PA, Potters L, Khuntia D, Ciezki JP, Reddy CA, Reuther AM, Carlson TP, Klein EA.

Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):25-33.

PMID:
14697417
10.

High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results.

Demanes DJ, Rodriguez RR, Schour L, Brandt D, Altieri G.

Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1306-16. Review.

PMID:
15817332
12.

Prognostic significance of 5-year PSA value for predicting prostate cancer recurrence after brachytherapy alone and combined with hormonal therapy and/or external beam radiotherapy.

Stock RG, Klein TJ, Cesaretti JA, Stone NN.

Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):753-8. doi: 10.1016/j.ijrobp.2008.08.049. Epub 2008 Dec 10.

PMID:
19084351
13.

Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.

Martinez AA, Demanes DJ, Galalae R, Vargas C, Bertermann H, Rodriguez R, Gustafson G, Altieri G, Gonzalez J.

Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1322-31.

PMID:
16029788
14.

Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995.

Thames H, Kuban D, Levy L, Horwitz EM, Kupelian P, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A.

Int J Radiat Oncol Biol Phys. 2003 Nov 15;57(4):929-43.

PMID:
14575823
15.

Combination conformal radiotherapy and radioimmunoguided transperineal 103Pd implantation for patients with intermediate and unfavorable risk prostate adenocarcinoma.

Ellis RJ, Vertocnik A, Sodee B, Zhou H, Kim E, Young B, Fu P, Colussi V, Spirnak JP, Dinchman KH, Resnick MI.

Brachytherapy. 2003;2(4):215-22.

PMID:
15062129
16.

The impact of irregularly rising prostate-specific antigen and "impending failure" on the apparent outcome of localized prostate cancer following radiotherapy.

Hodgson DC, Catton CN, Warde P, Gospodarowicz MK, Milosevic MF, McLean M B M, Catton P.

Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):957-63.

PMID:
11240236
17.

Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy.

Merrick GS, Butler WM, Wallner KE, Galbreath RW, Lief JH, Allen Z, Adamovich E.

Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):32-43.

PMID:
15629591
18.

Dose-response characteristics of low- and intermediate-risk prostate cancer treated with external beam radiotherapy.

Cheung R, Tucker SL, Lee AK, de Crevoisier R, Dong L, Kamat A, Pisters L, Kuban D.

Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):993-1002.

PMID:
15752878
19.

Brachytherapy or conformal external radiotherapy for prostate cancer: a single-institution matched-pair analysis.

Pickles T, Keyes M, Morris WJ.

Int J Radiat Oncol Biol Phys. 2010 Jan 1;76(1):43-9. doi: 10.1016/j.ijrobp.2009.01.081. Epub .

PMID:
19570619
20.

Equivalent biochemical control and improved prostate-specific antigen nadir after permanent prostate seed implant brachytherapy versus high-dose three-dimensional conformal radiotherapy and high-dose conformal proton beam radiotherapy boost.

Jabbari S, Weinberg VK, Shinohara K, Speight JL, Gottschalk AR, Hsu IC, Pickett B, McLaughlin PW, Sandler HM, Roach M 3rd.

Int J Radiat Oncol Biol Phys. 2010 Jan 1;76(1):36-42. doi: 10.1016/j.ijrobp.2009.01.029. Epub .

PMID:
19409729
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk